IP Verse

Combination Therapy For Inhalation Administration

Patent No. EP4188327 (titled "Combination Therapy For Inhalation Administration") was filed by Chemo Research on Jul 30, 2021. The application was issued on May 28, 2025.

Patent Summary

A pharmaceutical composition for soft mist inhaler administration comprising a combination of an inhaled corticosteroid (ICS) with a long-acting β2-agonist (LABA) and optionally a long-acting muscarinic antagonist (LAMA) for treating respiratory diseases such as asthma and COPD. The composition is a solution of the active ingredients dissolved in an alcoholic solvent, which provides higher lung deposition compared to other pharmaceutical forms. The formulation is free of propellant, stabilizing agents, and preservatives, and is suitable for use in a soft mist inhaler.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
MURGITROYDFeb 27, 2026MURGITROYD
SCORPIOFeb 27, 2026SAGITTARIUS
BRAND MURRAY FULLERFeb 26, 2026BRAND MURRAY FULLER
HIGHTONE MANAGEMENTOct 1, 2025GILL JENNINGS & EVERY

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP4188327

CHEMO RESEARCH
Application Number
EP21755917A
Filing Date
Jul 30, 2021
Status
Granted And Under Opposition
Apr 25, 2025
Publication Date
May 28, 2025
External Links
Slate, Register , Google Patents